Monica de Gaetano

Monica de Gaetano

Auto-generated profile, based on publicly available information

Monica de Gaetano

University College Dublin

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
MGMonica de Gaetano
Monica de Gaetano
DCDaniel Crean
Daniel Crean
MBMary Barry
Mary Barry
OBOrina Belton
Orina Belton
Atherosclerosis is an inflammatory disease caused by endothelial injury, lipid deposition and oxidative stress. This progressive disease can be converted into an acute clinical event by plaque rupture and thrombosis. In the context of atherosclerosis, the underlying cause of myocardial infarction and stroke, macrophages uniquely possess a dual functionality, regulating lipid accumulation and metabolism and sustaining the chronic inflammatory response, two of the most well documented pathways associated with the pathogenesis of the disease. Macrophages are heterogeneous cell populations and it is hypothesized that, during the pathogenesis of atherosclerosis, macrophages in the developing plaque can switch from a pro-inflammatory (MΦ1) to an anti-inflammatory (MΦ2) phenotype and vice versa, depending on the microenvironment. The aim of this study was to identify changes in macrophage subpopulations in the progression of human atherosclerotic disease. Established atherosclerotic plaques from symptomatic and asymptomatic patients with existing coronary artery disease undergoing carotid endarterectomy were recruited to the study. Comprehensive histological and immunohistochemical analyses were performed to quantify the cellular content and macrophage subsets of atherosclerotic lesion. In parallel, expression of MΦ1 and MΦ2 macrophage markers were analysed by real time-PCR and Western blot analysis. Gross analysis and histological staining demonstrated that symptomatic plaques presented greater haemorrhagic activity and the internal carotid was the most diseased segment, based on the predominant prevalence of fibrotic and necrotic tissue, calcifications and haemorrhagic events. Immunohistochemical analysis showed that both MΦ1 and MΦ2 macrophages are present in human plaques. However, MΦ2 macrophages are localised to more stable locations within the lesion. Importantly, gene and protein expression analysis of MΦ1/ MΦ2 markers evidenced that MΦ1 markers and Th1 associated cytokines are highly expressed in symptomatic plaques, whereas, expression of the MΦ2 markers, MR and CD163 and Th2 cytokines are inversely related with disease progression. This data increases the understanding of atherosclerosis development, identifying the cellular content of lesions during disease progression and characterising macrophage subpopulation within human atherosclerotic plaques.

9 May 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
EBEoin Brennan
Eoin Brennan
BWBo Wang
Bo Wang
AMAaron McClelland
Aaron McClelland
MMMuthukumar Mohan
Muthukumar Mohan
MMMariam Marai
Mariam Marai
PKPhillip Kantharidis
Phillip Kantharidis
The let-7 miRNA family plays a key role in modulating inflammatory responses. Vascular smooth muscle cell (SMC) proliferation and endothelial cell (EC) dysfunction are critical in the pathogenesis of atherosclerosis, including in the setting of diabetes. Here we report that let-7 levels are decreased in diabetic human carotid plaques and in a model of diabetes-associated atherosclerosis, the diabetic ApoE−/− mouse. In vitro platelet-derived growth factor (PDGF)– and tumor necrosis factor-α (TNF-α)–induced vascular SMC and EC activation was associated with reduced let-7 miRNA expression via Lin28b, a negative regulator of let-7 biogenesis. Ectopic overexpression of let-7 in SMCs inhibited inflammatory responses including proliferation, migration, monocyte adhesion, and nuclear factor-κB activation. The therapeutic potential of restoring let-7 levels using a let-7 mimic was tested: in vitro in SMCs using an endogenous anti-inflammatory lipid (lipoxin A4), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model. Furthermore, we delivered let-7 mimic to human carotid plaque ex vivo and observed significant changes to the secretome in response to let-7 therapy. Restoration of let-7 expression could provide a new target for an anti-inflammatory approach in diabetic vascular disease.

1 July 2008 in Neuropsychobiology
Verified
Journal Article
Closed access
PDF file
Marco SarchiaponeMarco Sarchiapone
Marco Sarchiapone
VCVladimir Carli
Vladimir Carli
ARAlec Roy
Alec Roy
LILicia Iacoviello
Licia Iacoviello
CCChiara Cuomo
Chiara Cuomo
MJMalvin N. Janal
Malvin N. Janal
Introduction: Recent post-mortem studies of suicide victims have implicated brain-derived neurotrophic factor (BDNF) in suicide. Therefore, it was decided to examine the possible role of a gene in the regulation of BDNF activity in relation to suicidal behaviour among depressed patients. Method: A series of 170 depressed patients were evaluated for their history of suicide attempts and genotyped for the BDNF Val66Met polymorphism (SNP ID: rs6265). Depressed patients who had (n = 97) or had not (n = 73) attempted suicide were compared. Results: Depressed patients who carried the BDNF Val66Met polymorphism variant (GA + AA) appeared to show a significantly increased risk of suicidal behaviour. The risk of a suicide attempt was also significantly higher among those reporting higher levels of childhood emotional, physical and sexual abuse. Secondary analyses suggested that depression severity was a significant risk factor only in the wild-type BDNF genotype, and that the risk of suicide attempts was more predictable within the wild-type group. Conclusion: These preliminary data suggest that BDNF may play a role in the suicidal behaviour of depressed patients.

13 September 2018 in Diabetes
Verified
Journal Article
Closed access
PDF file
EBEoin Brennan
Eoin Brennan
MMMuthukumar Mohan
Muthukumar Mohan
AMAaron McClelland
Aaron McClelland
MGMonica de Gaetano
Monica de Gaetano
CTChristos Tikellis
Christos Tikellis
PKPhillip Kantharidis
Phillip Kantharidis
Increasing evidence points to the fact that defects in the resolution of inflammatory pathways predisposes individuals to the development of chronic inflammatory diseases, including diabetic complications such as accelerated atherosclerosis. Resolution of inflammation is dynamically regulated by the production of endogenous modulators of inflammation, including lipoxin A4 (LXA4). Here, we explored the therapeutic potential of LXA4 and a synthetic LX analogue [Benzo-LXA4] to modulate diabetic complications in the streptozotocin-induced diabetic ApoE-/- mice and in human carotid plaque tissue ex vivo. The development of diabetes-induced aortic plaques and inflammatory responses of aortic tissue including expression of vcam1, mcp-1, il-6 and il-1β was significantly attenuated by both LXA4 and Benzo-LXA4 in diabetic ApoE-/- mice. Importantly, in mice with established atherosclerosis, treatment with LXs for a 6 week period, initiated 10 weeks after diabetes onset, led to a significant reduction in aortic arch plaque development [19.22±2.01% (diabetic); 12.67±1.68% (diabetic+LXA4); 13.19±1.97% (diabetic+Benzo-LXA4)]. Secretome profiling of human carotid plaque explants treated with LXs indicated changes to proinflammatory cytokine release, including TNF-α and IL-1β. LXs also inhibited PDGF-stimulated vascular smooth muscle cells proliferation and transmigration and endothelial cell inflammation. These data suggest that LXs may have therapeutic potential in the context of diabetes associated vascular complications.

27 April 2021 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
SOSilvia Oggero
Silvia Oggero
MGMonica de Gaetano
Monica de Gaetano
SMSimone Marcone
Simone Marcone
SFStephen Fitzsimons
Stephen Fitzsimons
APAndreia L. Pinto
Andreia L. Pinto
MPMauro Perretti
Mauro Perretti
Extracellular vesicles (EVs) are emerging as key players in different stages of atherosclerosis. Here we provide evidence that EVs released by mixed aggregates of monocytes and platelets in response to TNF‐α display pro‐inflammatory actions on endothelial cells and atherosclerotic plaques. Tempering platelet activation with Iloprost, Aspirin or a P2Y12 inhibitor impacted quantity and phenotype of EV produced. Proteomics of EVs from cells activated with TNF‐α alone or in the presence of Iloprost revealed a distinct composition, with interesting hits like annexin‐A1 and gelsolin. When added to human atherosclerotic plaque explants, EVs from TNF‐α stimulated monocytes augmented release of cytokines. In contrast, EVs generated by TNF‐α together with Iloprost produced minimal plaque activation. Notably, patients with coronary artery disease that required percutaneous coronary intervention had elevated plasma numbers of monocyte, platelet as well as double positive EV subsets. In conclusion, EVs released following monocyte/platelet activation may play a potential role in the development and progression of atherosclerosis. Whereas attenuating platelet activation modifies EV composition released from monocyte/platelet aggregates, curbing their pro‐inflammatory actions may offer therapeutic avenues for the treatment of atherosclerosis.

1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MGMonica de Gaetano
Monica de Gaetano
EBEibhlín Butler
Eibhlín Butler
KGKevin Gahan
Kevin Gahan
AZAndrea Zanetti
Andrea Zanetti
MMMariam Marai
Mariam Marai
PGPatrick J. Guiry
Patrick J. Guiry